NYSE:HAE Haemonetics (HAE) Stock Forecast, Price & News $86.48 +1.88 (+2.22%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$84.43▼$86.6250-Day Range$76.08▼$89.4552-Week Range$58.23▼$91.39Volume236,596 shsAverage Volume362,823 shsMarket Capitalization$4.37 billionP/E Ratio38.78Dividend YieldN/APrice Target$103.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Haemonetics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside19.3% Upside$103.17 Price TargetShort InterestHealthy2.16% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment1.07Based on 18 Articles This WeekInsider TradingSelling Shares$191,992 Sold Last QuarterProj. Earnings Growth11.55%From $3.55 to $3.96 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector529th out of 1,980 stocksSurgical & Medical Instruments Industry57th out of 200 stocks 2.3 Analyst's Opinion Consensus RatingHaemonetics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.17, Haemonetics has a forecasted upside of 19.3% from its current price of $86.48.Amount of Analyst CoverageHaemonetics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.16% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Haemonetics has recently increased by 3.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHaemonetics has received a 64.94% net impact score from Upright. Haemonetics seems to create the most significant positive value in categories "Taxes", "Physical diseases", and "Relationships". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Computerized clinical decision support software", "Hemofilters", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Haemonetics is -0.54. Previous Next 3.9 News and Social Media Coverage News SentimentHaemonetics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Haemonetics this week, compared to 5 articles on an average week.Search Interest4 people have searched for HAE on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Haemonetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,992.00 in company stock.Percentage Held by InsidersOnly 1.65% of the stock of Haemonetics is held by insiders. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Haemonetics are expected to grow by 11.55% in the coming year, from $3.55 to $3.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 38.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 38.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.86.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 2.35. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Haemonetics (NYSE:HAE) StockHaemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.Read More Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Email Address HAE Stock News HeadlinesJune 1, 2023 | finance.yahoo.comHaemonetics (HAE) Hospital Arm Grows, Plasma Volume ImprovesMay 31, 2023 | americanbankingnews.comHaemonetics Co. Expected to Post Q1 2024 Earnings of $0.73 Per Share (NYSE:HAE)June 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 28, 2023 | americanbankingnews.comFinancial Analysis: Haemonetics (NYSE:HAE) versus Modular Medical (OTC:MODD)May 26, 2023 | finance.yahoo.comHow Much Upside is Left in Haemonetics (HAE)? Wall Street Analysts Think 27.09%May 26, 2023 | americanbankingnews.comHaemonetics Co. Expected to Post FY2026 Earnings of $4.66 Per Share (NYSE:HAE)May 26, 2023 | americanbankingnews.comStockNews.com Upgrades Haemonetics (NYSE:HAE) to Strong-BuyMay 18, 2023 | seekingalpha.comHaemonetics Corporation: Premium Blood PlayJune 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 16, 2023 | msn.comHaemonetics: Attracting Investment Through Capital Recycling InitiativesMay 16, 2023 | americanbankingnews.comHaemonetics (NYSE:HAE) Upgraded to Strong-Buy at StockNews.comMay 16, 2023 | americanbankingnews.comJMP Securities Raises Haemonetics (NYSE:HAE) Price Target to $115.00May 16, 2023 | marketwatch.comDisposable Blood Filters Market 2023 Insights with Statistics and Growth Prediction - Haemonetics, Asahi Kasei Medical, Fresenius, MacopharmaMay 16, 2023 | marketwatch.comWhen Haemonetics ($HAE) Moves Investors should ListenMay 15, 2023 | americanbankingnews.comHaemonetics (NYSE:HAE) Releases FY 2024 Earnings GuidanceMay 13, 2023 | msn.comBarrington Research Maintains Haemonetics (HAE) Outperform RecommendationMay 13, 2023 | americanbankingnews.comHaemonetics (NYSE:HAE) Price Target Raised to $111.00 at Barrington ResearchMay 12, 2023 | marketwatch.comGlobal Automatic Hemostasis Analyzers Market Size 2023-2031 Competitive Landscape by Absolute Reports | with [95 Pages]May 12, 2023 | marketwatch.comGlobal Auto Transfusion System Market Size 2023-2031 Business Strategies by Absolute Reports | with [87 Pages]May 12, 2023 | markets.businessinsider.comBarrington Reaffirms Their Buy Rating on Haemonetics (HAE)May 12, 2023 | marketwatch.comApheresis Machines Market Research and Size Analysis 2023-2030May 12, 2023 | msn.comJMP Securities Maintains Haemonetics (HAE) Market Outperform RecommendationMay 12, 2023 | msn.comMorgan Stanley Maintains Haemonetics (HAE) Equal-Weight RecommendationMay 12, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (CRSP), Haemonetics (HAE) and TFF Pharmaceuticals (TFFP)May 11, 2023 | marketwatch.com2030, Blood Filtration Market ResearchMay 11, 2023 | washingtonpost.comHaemonetics: Fiscal Q4 Earnings SnapshotMay 11, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About Haemonetics (HAE) Q4 EarningsSee More Headlines HAE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HAE Company Calendar Last Earnings2/07/2023Today6/01/2023Next Earnings (Estimated)8/09/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNYSE:HAE CUSIP40502410 CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,034Year Founded1971Price Target and Rating Average Stock Price Forecast$103.17 High Stock Price Forecast$115.00 Low Stock Price Forecast$88.00 Forecasted Upside/Downside+20.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$2.23 Trailing P/E Ratio38.34 Forward P/E Ratio24.08 P/E Growth2.35Net Income$115.40 million Net Margins9.87% Pretax Margin12.10% Return on Equity20.13% Return on Assets8.31% Debt Debt-to-Equity Ratio0.92 Current Ratio3.06 Quick Ratio2.03 Sales & Book Value Annual Sales$1.17 billion Price / Sales3.70 Cash Flow$5.10 per share Price / Cash Flow16.77 Book Value$16.18 per share Price / Book5.28Miscellaneous Outstanding Shares50,540,000Free Float49,707,000Market Cap$4.32 billion OptionableOptionable Beta0.44 Social Links Key ExecutivesChristopher A. SimonPresident, Chief Executive Officer & DirectorJames C. DareccaExecutive VP, Chief Financial & Accounting OfficerAnila LingamneniChief Technology Officer & Executive VPLaurie A. MillerChief Human Resources Officer & Senior VPDavid James WilsonPresident-Plasma Business UnitKey CompetitorsICU MedicalNASDAQ:ICUIMerit Medical SystemsNASDAQ:MMSIiRhythm TechnologiesNASDAQ:IRTCInari MedicalNASDAQ:NARIGlobus MedicalNYSE:GMEDView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 2,226 shares on 6/1/2023Ownership: 0.059%ProShare Advisors LLCSold 1,518 shares on 5/26/2023Ownership: 0.018%Legato Capital Management LLCSold 302 shares on 5/25/2023Ownership: 0.006%Toroso Investments LLCSold 2,525 shares on 5/23/2023Ownership: 0.006%Ameriprise Financial Inc.Bought 14,366 shares on 5/22/2023Ownership: 0.912%View All Insider TransactionsView All Institutional Transactions HAE Stock - Frequently Asked Questions Should I buy or sell Haemonetics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HAE shares. View HAE analyst ratings or view top-rated stocks. What is Haemonetics' stock price forecast for 2023? 6 Wall Street research analysts have issued 1 year price targets for Haemonetics' shares. Their HAE share price forecasts range from $88.00 to $115.00. On average, they expect the company's stock price to reach $103.17 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View analysts price targets for HAE or view top-rated stocks among Wall Street analysts. How have HAE shares performed in 2023? Haemonetics' stock was trading at $78.65 at the beginning of 2023. Since then, HAE shares have increased by 8.7% and is now trading at $85.49. View the best growth stocks for 2023 here. Are investors shorting Haemonetics? Haemonetics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,040,000 shares, a decrease of 21.2% from the April 15th total of 1,320,000 shares. Based on an average daily volume of 328,200 shares, the days-to-cover ratio is presently 3.2 days. Currently, 2.1% of the shares of the stock are sold short. View Haemonetics' Short Interest. When is Haemonetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our HAE earnings forecast. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) announced its earnings results on Tuesday, February, 7th. The medical instruments supplier reported $0.85 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.79 by $0.06. The medical instruments supplier earned $305.30 million during the quarter, compared to the consensus estimate of $300.47 million. Haemonetics had a trailing twelve-month return on equity of 20.13% and a net margin of 9.87%. The business's revenue for the quarter was up 17.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.84 EPS. What ETFs hold Haemonetics' stock? ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco DWA Healthcare Momentum ETF (PTH), Invesco S&P MidCap Momentum ETF (XMMO), Harbor Health Care ETF (MEDI), Cultivar ETF (CVAR), First Trust Mid Cap Growth AlphaDEX Fund (FNY), First Trust Active Factor Mid Cap ETF (AFMC) and Fidelity Small-Mid Cap Opportunities ETF (FSMO). What guidance has Haemonetics issued on next quarter's earnings? Haemonetics updated its FY 2024 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $3.45-$3.75 for the period, compared to the consensus EPS estimate of $3.40. The company issued revenue guidance of $1.22 billion-$1.25 billion, compared to the consensus revenue estimate of $1.22 billion. What is Christopher Simon's approval rating as Haemonetics' CEO? 48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE). What is Haemonetics' stock symbol? Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE." Who are Haemonetics' major shareholders? Haemonetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.09%), Fisher Asset Management LLC (2.07%), Geode Capital Management LLC (1.87%), Royce & Associates LP (1.67%), Dimensional Fund Advisors LP (1.39%) and Boston Partners (1.32%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Haemonetics' stock price today? One share of HAE stock can currently be purchased for approximately $85.49. How much money does Haemonetics make? Haemonetics (NYSE:HAE) has a market capitalization of $4.32 billion and generates $1.17 billion in revenue each year. The medical instruments supplier earns $115.40 million in net income (profit) each year or $2.23 on an earnings per share basis. How many employees does Haemonetics have? The company employs 3,034 workers across the globe. How can I contact Haemonetics? Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106. This page (NYSE:HAE) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.